Prospective Evaluation of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: The Stenting Of Saphenous Vein Grafts Xience V Angiographic Study (SOS-Xience V).
Phase of Trial: Phase IV
Latest Information Update: 25 Oct 2012
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms SOS-Xienc-V
- 15 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 02 Aug 2010 Planned end date changed from 1 May 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 02 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.